CSIMarket


Inhibrx Inc   (INBX)
Other Ticker:  
 


 

Inhibrx Inc

INBX's Financial Statements and Analysis



Inhibrx Inc increased forth quarter of 2023 net loss per share of $-1.50 compare to net loss per share of $-0.92 recorded in the same quarter a year ago a decrease compare to $-1.10 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -1.5 $  2 Mill
$-0.58     $+1M     +496.35 %



Inhibrx Inc 's Revenue rose by 496.35 % in forth quarter of 2023 (Dec 31 2023) year on year, to $2 million and advanced by 1273.11 % sequentially.


Inhibrx Inc is

More on INBX's Income Statement



Inhibrx Inc 's in theforth quarter of 2023 recorded net loss of $-93.604 million, an increase from net loss of $-40.915 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on INBX's Growth

Inhibrx Inc Inventories
In Dec 31 2023 company's net cash and cash equivalents decreased by $-59 million

More on INBX's Cash flow Statement


Inhibrx Inc does not pay out common stock dividend.

In trailing twelve-month period Inhibrx Inc payed $ -4.10 cash per share, on a free-cash flow basis .

Book value fell by -66.42 % sequentially to $0.92 per share, -38.00% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.92 per share from $ 2.75.

Company repurchased 0.01 million shares or 0.02 % in Dec 31 2023.


More on INBX's Dividends

 Market Capitalization (Millions) 1,653
 Shares Outstanding (Millions) 47
 Total Debt (Millions $) 207
 Revenue (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -241
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) -5
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Inhibrx Inc does not pay out common stock dividend.

In trailing twelve-month period Inhibrx Inc had negative $ -4.10 cash flow per share, on a free-cash flow basis .

Book value fell by -66.42 % sequentially to $0.92 per share, -38.00% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value fell to $ 0.92 per share from $ 2.75.

Company repurchased 0.01 million shares or 0.02 % in Dec 31 2023.


More on INBX's Balance Sheets

 Market Capitalization (Millions) 1,653
 Shares Outstanding (Millions) 47
 Total Debt (Millions $) 207
 Revenue (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -241
 Cash Flow (TTM) (Millions $) 4
 Capital Exp. (TTM) (Millions $) -5
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Inhibrx Inc Earnings

Inhibrx Inc Faces Profitability Challenges Despite Revenue Surge in Q4 2023

Inhibrx Inc, a biotechnology and pharmaceuticals company, has announced impressive financial results for the fourth quarter of 2023. Despite the challenging market conditions faced by many companies in the sector, Inhibrx Inc saw a significant improvement in revenue, with a 496.35% year-on-year increase to $1.63 million. However, the company also reported an increased shortfall per share at $-1.50.
Compared to the previous reporting period, the shortfall per share advanced from $-1.10, while revenue more than doubled by 1273.109% from $0.12 million. Inhibrx Inc's net shortfall for the fourth quarter of 2023 was $-93.604 million, which is larger than the $-40.915 million reported in the same period a year...

Headline: Diminishing Returns Expand at Biotechnology & Pharmaceuticals Company Throughout July-September 2023 Fiscal Period, Inhibrx Inc. Takes More Sophisticated Approach

Inhibrx Inc, a biopharmaceutical company, has recently disclosed its third quarter financial report for 2023, which showed a significant decline in revenue. T...

Inhibrx Inc Reports Soaring Demand and Growth Potential Amidst Major Financial Setback



Inhibrx Inc, a pharmaceutical company, recently relea...

Inhibrx Inc: Battling Adversity Throughout the First Quarter of 2023

Inhibrx Inc is a biotechnology company that specializes in developing novel biologic medicines for the treatment of serious and life-threatening diseases. The company focuses on developing antibodies that target specific proteins involved in the progression of diseases, with the goal of blocking their activity and stopping the disease from progressing.
Despite its impressive research and development efforts, Inhibrx has had a difficult start to 2023. In a recent announcement, the company reported disastrous financial results, with revenue falling by -98.17% to just $0.02 million for the period of January to March 31 2023. This is a significant decline compared to the corresponding reporting period a year...


Date modified: 2024-02-28T20:33:07+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com